Gencurix supplies companion diagnostic kits to cancer center in India
The Tata Memorial Centre in Mumbai is getting the Droplex POLE Mutation Test for genetic diagnosis of endometrial cancer
By Aug 18, 2023 (Gmt+09:00)
Deutsche Bank's Korea IB head quits after country head resigns
Hanwha buys S’pore Dyna-Mac’s stake for $73.8 mn from Keppel
Macquarie Korea Asset Management confirms two nominees
Meritz leaves door open for an M&A, to stay shareholder friendly
Korea's Taeyoung to sell local hotel to speed up debt workout
South Korean biotech company Gencurix Inc. on Friday said it started supplying its companion diagnostic test Droplex to a national cancer center in India.
Gencurix is supplying its companion diagnostic product Droplex POLE Mutation Test. A related device uses the droplet digital PCR platform to analyze the genes of endometrial cancer patients and check for mutations.
This year, India is expected to overtake China as the world's most populous country per the United Nations. With 1.4 billion people, the South Asian country is seeing a surge in endometrial cancer due to the spread of diagnostic tests and changes in eating habits.
"Using this introduction case as reference, we plan to make our test available at other major hospitals in India," a Gencurix source said. "Aside from this product, we're promoting the sale of other companion diagnostic test kits."
Write to In-Hyuk Park at hyuk@hankyung.com